- OxPhos System Evolution Explored, Indicating Links Between Mutations and Disease
- Unlocking the Mystery Behind Barrett’s Esophagus
- STING Inhibition Differences Revealed Between Humans and Mice
- Unnatural Products, Argenx Partner on Macrocyclic Peptides for Immune Disease
- LICORbio Acquires Serva Electrophoresis
Search results
-
H
FMT Safety Questioned: Microbiome Mismatches May Have Unintended Health Effects
Fecal microbiota transplants (FMT) have been touted as a potential treatment for a variety of conditions, from inflammatory bowel diseases (IBDs), obesity, and type 2 diabetes, to autism. The results of new research carried out by researchers at the University of Chicago, now caution against... -
H
Disrupting Mechanical Transmission by Titin Protein Precipitates Muscle Diseases
A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative method known as TEVs-TTN, for studying the specific mechanical functions of proteins through their controlled cleavage. This process renders the proteins unable to sense and transmit mechanical... -
H
Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”
Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy recommendations with leaders of the FDA in an extraordinary roundtable. The roundtable was... -
H
In a First, Mitochondrial Mutation Tied to Melanoma Checkpoint Resistance
It often starts with something small—a dark spot on the skin that looks a little off. A dermatologist takes a closer look, runs a biopsy, and soon after, the diagnosis arrives: melanoma. If the cancer is advanced, treatment may include immune checkpoint inhibitors—drugs that help the body’s own... -
H
CSF Flow Enhanced Through Non-Invasive Manipulation of Lymphatics
Scientists at the Institute for Basic Science (IBS) have uncovered a non-invasive method to boost the brain’s natural waste drainage system—a discovery that they suggest could open new avenues for tackling age-related neurological disorders. The team, led by IBS Center for Vascular Research... -
H
What is the Risk of MERS-Like Bat Viruses Infecting Humans?
Middle East Respiratory Syndrome Coronavirus (MERS-CoV), a zoonotic pathogen transmitted from dromedary camels to humans that causes severe respiratory disease with a mortality rate of approximately 34%, belongs to the merbecovirus subgenus of coronaviruses. To better understand how the... -
H
AI-Enhanced Zinc Finger Proteins May Reduce Immune Risks in Cell and Gene Therapies
Stanford University researchers are using machine learning algorithms to modify human proteins with an eye toward improving the efficacy and safety of targeted cell and gene therapies by reducing the risks of an adverse immune response. Details of the work are published in a new Cell Systems... -
H
Multiomics Profiling of Blood Sugar Responses Provides Window to Metabolic Health
A study led by researchers at Stanford Medicine has shown that differences in blood sugar responses to certain carbohydrates depend on details of an individual’s metabolic health status, including specific metabolic conditions such as insulin resistance or beta cell dysfunction, both of which... -
H
Medicines Discovery Catapult and the Francis Crick Institute Partner to Support KQ Labs’ Accelerator Program
Medicines Discovery Catapult (MDC) and the Francis Crick Institute formed a strategic partnership to support the delivery of KQ Labs, founded and hosted by the Crick. The KQ Labs program is an annual five-month accelerator for up to ten U.K.-based startups building science-backed, data-driven... -
H
U.K.’s First Official Guidance to Support Safe Development and Use of Phage Therapies Published
The Medicines and Healthcare products Regulatory Agency (MHRA) has published the U.K.’s first official guidance to support the safe development and use of phage therapies. The guidance aims to help researchers and companies develop phage-based medicines that meet U.K. safety, quality and... -
H
AMR May Meet Its Match: New Compound Shows Preclinical Promise
Antimicrobial resistance (AMR) is outpacing drug discovery—and killing more than a million people each year. As frontline antibiotics lose their effectiveness, healthcare systems around the world face a rising tide of infections that no longer respond to treatment. The World Health Organization... -
H
Research Tool Generates Aneuploid Cells to Study Fertility and Cancer
Errors in chromosome segregation cause more than 80% of early human embryos to contain cells with an incorrect number of chromosomes, a phenomenon called aneuploidy. While aneuploid cells are normally depleted from embryonic germ layers to give rise to healthy births, the emergence of aneuploidy... -
H
BMS, BioNTech Ink Up-to-$11B Cancer Bispecific Antibody Collaboration
Bristol Myers Squibb (BMS) has agreed to co-develop and co-commercialize BioNTech’s cancer-fighting bispecific antibody candidate BNT327 across numerous solid tumor types through a collaboration that could generate up to $11.1 billion for the German next-generation immunotherapy developer, the... -
H
Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I
Kymera Therapeutics has announced positive results in an early-stage Phase I trial for an investigational drug designed to treat millions of patients experiencing symptoms of chronic inflammation and allergic reactions. This spectrum of targeted conditions, known as Th2 diseases, is... -
H
Diminished Stress Response in Aging Neurons Linked to Neurodegeneration
As people age, their risk of developing neurodegenerative disorders like dementia, Alzheimer’s disease, and Parkinson’s disease increases. A new study from scientists at the University of California, San Diego (UCSD), helps elucidate some of the molecular mechanisms behind why brain cells... -
H
PD-1 Regulates CD30, Curbs T Cell Suppression in Melanoma
The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, by an international group of scientists headed by a team at Newcastle University, also points... -
H
Cocaine Addicted Drosophila May Accelerate Discoveries
Little is known about the specific genes and mechanisms that lead to the development of cocaine use disorder and there are currently no FDA-approved pharmacotherapies that can treat it. However, it continues to be a growing and deadly concern that affects about 1.5 million people nationwide... -
H
Insilico Eyes Q4 Start for Late-Stage Trials of IPF Candidate
Artificial intelligence (AI) drug developer Insilico Medicine says it is planning late-stage trials for its lead clinical candidate rentosertib following publication today of positive mid-stage safety and efficacy data for the idiopathic pulmonary fibrosis (IPF) candidate. Rentosertib (formerly... -
H
Dual-Target CAR-T Cell Therapy Slows Glioblastoma Tumors in Phase I Trial
Glioblastoma (GBM) is an aggressive and common brain cancer in adults with average life expectancies of 12–18 months after diagnosis and median survival rate for recurrent GBM ranging from 6–10 months. In a new study presented at the 2025 American Society of Clinical Oncology (ASCO) annual... -
H
Sanofi to Acquire Blueprint Medicines for Up to $9.5B
Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an FDA-approved treatment, as well as an early-stage pipeline of immunological drug candidates. The...